You are here

Study Evaluating IMA-638 in Asthma

Last updated on May 12, 2018

FOR MORE INFORMATION
Study Location
Denver, Colorado, 80230 United States
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Asthma
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-50 years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Men and women of non-childbearing potential with mild to moderate asthma as defined by
forced expiratory volume in 1 second (FEV1) greater than 70% predicted.

- Well controlled asthma, as exhibited by completion of asthma questionnaire.

- Otherwise healthy, except for asthma.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Men and women of non-childbearing potential with mild to moderate asthma as defined by
forced expiratory volume in 1 second (FEV1) greater than 70% predicted.

- Well controlled asthma, as exhibited by completion of asthma questionnaire.

- Otherwise healthy, except for asthma.

NCT00339872
Pfizer
Completed
Study Evaluating IMA-638 in Asthma

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.

Similar Trials

Asthma, Diabetes Mellitus
NCT00139659
All Genders
18+
Years
Multiple Sites
Asthma
NCT00150397
All Genders
18+
Years
Multiple Sites
Asthma
NCT00339872
All Genders
18+
Years
Denver, Colorado
Asthma
NCT00141791
All Genders
18+
Years
Multiple Sites
Study Evaluating IMA-638 in Asthma
Randomized, Double-Blind, Placebo-Controlled, Sequential-Group, Ascending Single Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IMA-638 Administered Subcutaneously and Intravenously to Subjects With Asthma
The purpose of this study is to evaluate the safety of, and blood drug levels for, single, ascending doses of IMA-638 in mild to moderate asthma subjects.
Not Provided
Interventional
Phase 1
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Double
Primary Purpose: Diagnostic
Asthma
Drug: IMA-638
Not Provided
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
Not Provided
April 2007
Not Provided

Inclusion Criteria:

  • Men and women of non-childbearing potential with mild to moderate asthma as defined by forced expiratory volume in 1 second (FEV1) greater than 70% predicted.
  • Well controlled asthma, as exhibited by completion of asthma questionnaire.
  • Otherwise healthy, except for asthma.
Sexes Eligible for Study: All
18 Years to 50 Years   (Adult)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT00339872
3174K1-100
Not Provided
Not Provided
Not Provided
Not Provided
Wyeth is now a wholly owned subsidiary of Pfizer
Not Provided
Study Director: Medical Monitor Wyeth is now a wholly owned subsidiary of Pfizer
Wyeth is now a wholly owned subsidiary of Pfizer
December 2007

ICMJE     Data element required by the

International Committee of Medical Journal Editors
and the
World Health Organization ICTRP

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now